NCT04778579View on ClinicalTrials.gov

Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 11, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Acute Lymphoid Leukemia
Interventions
DRUG

ARI-0001 cells

Adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z

Trial Locations (9)

28007

Hospital General Universitario Gregorio Marañón, Madrid

28041

Hospital 12 de Octubre, Madrid

30120

Hospital Clínico Universitario Virgen de La Arrixaca, Murcia

31008

Clínica Universidad de Navarra, Pamplona

37007

Hospital Universitario de Salamanca, Salamanca

41013

Hospital U. Virgen del Rocío, Seville

08916

Hospital Universitari Germans Trias i Pujol, Badalona

08036

Hospital Clinic of Barcelona, Barcelona

08041

Hospital de la Santa Creu i Sant Pau, Barcelona

All Listed Sponsors
collaborator

Institut d'Investigacions Biomèdiques August Pi i Sunyer

OTHER

collaborator

Instituto de Salud Carlos III

OTHER_GOV

lead

Sara V. Latorre

OTHER